Bombesin
Also known as: BBN, BN, Bombesin, Frog bombesin, Gastrin-releasing peptide amphibian homolog, Litorin-related peptide
Source Bombesin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Bombesin is a 14‑amino‑acid peptide originally isolated from the skin of the European frog Bombina bombina. It is a natural analogue of human gastrin‑releasing peptide (GRP) and binds with high affinity to the GRP receptor (GRPR) and related bombesin receptors. In research, bombesin‑derived ligands are explored primarily for cancer imaging and as vectors to deliver therapeutic agents to tumors that over‑express GRPR.
Mechanism of Action
Bombesin binds to G‑protein‑coupled bombesin receptors—principally the GRPR (BB2) but also NMB (BB1), BB3 and BB4 subtypes. Ligand binding triggers intracellular calcium influx and activation of downstream signaling cascades that promote cell proliferation and secretion. In the imaging context, the peptide serves as a high‑affinity targeting moiety that can be labeled with radionuclides, allowing receptor‑mediated accumulation of the imaging probe in GRPR‑positive tissues.
What the Research Shows
Reviews published in 2015 and 2016 note that GRPR is over‑expressed in many common cancers, including breast, prostate, lung, colon, ovarian and pancreatic tumours. This has driven the design of bombesin‑based radioligands such as 68Ga‑RM2, 111In‑RM1, 99mTc‑RGD‑Bombesin and 18F‑FB‑Bombesin‑RGD, which have shown high affinity and selective tumour uptake in pre‑clinical PET/SPECT studies. Antagonist analogues (e.g., RM26‑derived compounds) are being developed to improve imaging contrast while avoiding receptor activation. The literature also discusses using bombesin ligands to deliver cytotoxic payloads, but no clinical efficacy data are presented.
Reported Benefits
Bombesin‑derived ligands provide very high specificity for GRPR‑positive tumours, enabling sensitive PET or SPECT imaging and the potential for targeted delivery of radionuclides or chemotherapeutic agents. Antagonist versions may retain binding while minimizing physiological stimulation, offering a safer imaging profile.
Limitations of the Evidence
Evidence is largely pre‑clinical; therapeutic benefit in patients has not been demonstrated. Receptor expression varies between tumour types and patients, which may limit universal applicability. Most reported agents are agonists, and the need for antagonist radioligands remains. No human safety or efficacy data are cited in the abstracts.
Safety Considerations
Bombesin peptides act as growth factors in normal CNS and gastrointestinal tissues, so systemic exposure could stimulate physiological pathways. Radiolabeled analogues add radiation exposure, and no adverse‑event information is provided in the cited literature. Until human studies are performed, safety cannot be assumed.
How It Is Administered
In experimental settings bombesin analogues are typically administered intravenously for PET or SPECT imaging. Other routes such as intracerebroventricular or subcutaneous injection are listed for research use. Compounds are formulated as peptide solutions, often chelated to radionuclides for imaging purposes.
Routes of Administration
Goals & Uses
- Appetite suppression / satiety signaling researchMetabolic / NeuroscienceModerate
- Targeted drug delivery vehicleOncology / Drug DeliveryLow
- Research tool for gastrointestinal hormone studiesBasic ResearchHigh
- GRPR‑directed radionuclide therapyTherapeutic TargetingModerate
- Cancer receptor imaging (prostate, breast, SCLC)Oncology / Nuclear MedicineModerate
- Thermoregulation researchNeuroscienceLow
- GI hormone secretion stimulationGastroenterologyModerate
- GRPR‑targeted PET imagingDiagnostic ImagingModerate
Contraindications
- Severe peptic ulcer diseaseGastroenterologyModerate
- Active GI obstruction or ileusGastroenterologyModerate
- Hypersensitivity to bombesin or related peptidesAllergy / ImmunologyHigh
Adverse Effects
- AnaphylaxisImmunologicRareSevere life-threatening allergic reaction
- Injection site reactionsLocalCommon
- HypotensionCardiovascularUnknownLow blood pressure
- FlushingVascularUnknownWarmth and redness of the skin
- Nausea and vomitingGastrointestinalCommon
- NauseaGastrointestinalUnknownFeeling of sickness or urge to vomit
- Abdominal crampingGastrointestinalCommon
Drug Interactions
- AnticholinergicsLow
- Proton pump inhibitors / H2 blockersLow
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatric populationsAgeRelative
- Pediatric useAgeRelative
- Renal or hepatic impairmentOrgan DysfunctionRelative
Regulatory Status
- European UnionUnapprovedNo marketing authorization; used in clinical trials.
- United StatesUnapprovedInvestigational use only under IND.
- United KingdomUnapprovedResearch use only.
Not approved for any therapeutic indication; employed only in pre‑clinical and early clinical research settings.
Evidence & Sources
- Journal ArticleModerateMoreno P, et al.2016-01-01T00:00:00.000000Z
- Journal ArticleModerateRamos-Álvarez I, et al.2015-01-01T00:00:00.000000Z
- Journal ArticleModerateLeung K2004-01-01T00:00:00.000000Z
- Journal ArticleModerateLeung K2004-01-01T00:00:00.000000Z
- Journal ArticleModerateLeung K2004-01-01T00:00:00.000000Z
- Journal ArticleModerateLeung K2004-01-01T00:00:00.000000Z
Frequently Asked Questions
What types of cancer might be visualized with bombesin‑based imaging?
Pre‑clinical work shows that tumours over‑expressing the GRP receptor—such as breast, prostate, lung, colon, ovarian and pancreatic cancers—can accumulate bombesin‑derived radioligands, allowing PET or SPECT visualization.
Are bombesin ligands used to treat cancer, or only to image it?
Current research focuses on imaging and on using bombesin as a delivery vehicle for cytotoxic agents. No clinical trials demonstrating therapeutic efficacy have been reported in the cited abstracts.
Why are antagonist bombesin analogues being developed?
Antagonists bind the receptor without triggering downstream signaling, which may reduce physiological side‑effects while preserving high tumour uptake, improving image contrast and safety.
What are the main safety concerns with bombesin‑based probes?
Potential concerns include stimulation of normal GRPR pathways in the brain and gut, and radiation exposure from the attached radionuclide. The abstracts do not provide human safety data.
How are bombesin imaging agents prepared for use?
The peptide is chemically linked to a chelator (e.g., DOTA, NOTA) that holds a radionuclide such as 68Ga, 111In, 99mTc, or 18F. The resulting radiolabeled peptide is dissolved in a sterile solution and given intravenously for imaging.
What is Bombesin?
Bombesin is a 14‑amino‑acid peptide originally isolated from the skin of the European frog Bombina bombina. It is a natural analogue of human gastrin‑releasing peptide (GRP) and binds with high affinity to the GRP receptor (GRPR) and related bombesin receptors. In research, bombesin‑derived ligands are explored primarily for cancer imaging and as vectors to deliver therapeutic agents to tumors that over‑express GRPR.
What is Bombesin used for?
Bombesin is educationally associated with: Appetite suppression / satiety signaling research, Targeted drug delivery vehicle, Research tool for gastrointestinal hormone studies, GRPR‑directed radionuclide therapy, Cancer receptor imaging (prostate, breast, SCLC), Thermoregulation research, GI hormone secretion stimulation, GRPR‑targeted PET imaging. Educational only — not medical advice.
How is Bombesin administered?
Recorded routes of administration: Intracerebroventricular, Intranasal, Intravenous, Subcutaneous.
What are the potential side effects of Bombesin?
Reported adverse effects include: Anaphylaxis, Injection site reactions, Hypotension, Flushing, Nausea and vomiting, Nausea, Abdominal cramping. This list is not exhaustive — consult a qualified clinician.
Who should avoid Bombesin?
Recorded contraindications: Severe peptic ulcer disease, Active GI obstruction or ileus, Hypersensitivity to bombesin or related peptides. Consult a qualified clinician before use.